GlassScriptPhysician profile
Hamzeh O Badwan
NPI 1205333994
$3,634.55
in general payments reported to CMS, 2019-2025
20 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.09 · 2022: $729 · 2023: $862 · 2024: $925 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,882 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,881.77 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $869.55 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $734.56 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $537.78 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $485.32 | 2023-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.47 | 2022-2025 | Jardiance |
| Amgen INC. | $101.90 | 2022-2025 | Repatha, Repatha, Otezla |
| Abbvie INC. | $101.50 | 2024-2025 | |
| Mylan Specialty L.P. | $84.46 | 2024 | Yupelri |
| Exact Sciences Corporation | $75.75 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $75.63 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.33 | 2023-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $59.38 | 2024 | Eliquis |
| Dexcom, INC. | $55.65 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $48.62 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $43.97 | 2025 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.41 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $36.25 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $27.08 | 2022 | |
| Viatris Specialty LLC | $18.65 | 2025 | Yupelri |
| Sobi, INC | $15.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamzeh Badwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.